HHS Secretary Disavows Role in FDA's Rejection of Replimune Skin Cancer Therapy
Health and Human Services Secretary Robert F. Kennedy Jr. told a Senate budget hearing he was not involved in the U.S. Food and Drug Administration's decision to decline approval of Replimune's investigational skin cancer therapy RP1, saying the matter rested with FDA Commissioner Dr. Marty Makary. The FDA cited insufficient evidence from a single-…